virtual incentive treatment for alcohol

Conditions: Alcohol Use Disorder; Alcohol Drinking; Alcohol Abuse; Alcohol Dependence

Summary: the overall objective of this program of research is to utilize phosphatidylethanol (peth), a blood-based biomarker that can detect alcohol use for up to 28 days to deliver a feasible telehealth-based 26-week cm intervention. this study will test a telehealth peth-based cm model in a sample of adults with aud (n=200), recruited via online platforms by randomizing individuals to six months of 1) an online cognitive behavioral therapy for aud (cbt4cbt) and telehealth peth-based cm (cm condition) or 2) cbt4cbt and reinforcers for submitting blood samples (no abstinence required) (control condition). investigators will assess group differences in peth-defined abstinence and regular excessive drinking (peth \>= 200 ng/ml), and alcohol-related harms (e.g., smoking, drug use). this study will address important gaps in cm research by assessing outcomes during a 12-month follow-up, which is much longer than most previous cm studies; using a conceptual model to identify predictors of post-treatment abstinence. investigators will conduct an economic analysis to place the cost of this model in the context of downstream cm-associated cost-offsets and improvements in personal and public health.

the overall objective of this study is to utilize phosphatidylethanol (peth), a blood-based biomarker that can detect alcohol use for up to 28 days to deliver a feasible telehealth-based 26-week cm intervention. in a pilot trial, we developed a telehealth-based peth cm intervention where participants used a medical device, the tasso-m20 to self-collect blood for peth testing under the observation of research staff over zoom. this intervention used a two-phase approach where the frequency of peth testing and reinforcement was decreased from once a week, to as infrequently as every four weeks once participants achieved a peth level consistent with two to four weeks of abstinence (\ 4 weeks of abstinence versus 21% of the treatment as usual (tau) group, and 43% of cm participants achieved \>24 weeks of abstinence compared to 0% of the tau group (p \ = 200 ng/ml), and alcohol-related harms (e.g., smoking, drug use). this study will address important gaps in cm research by assessing outcomes during a 12-month follow-up, which is much longer than most previous cm studies; using a conceptual model to identify predictors of post-treatment abstinence. the primary barrier to the dissemination of this model is the cost of peth testing and cm reinforcers. investigators will conduct an economic analysis to place these costs in the context of downstream cm-associated cost- offsets and improvements in personal and public health. if this model increases alcohol abstinence and is cost-effective it could reach millions of americans with aud that cannot or do not seek in-person care.

Eligibility criteria:
inclusion criteria: 1. had 2 heavy drinking episodes (assigned male at birth \> 4 standard drinks (sds), assigned female at birth \> 3 sds) or ≥14 sds in the prior 14 days verified by peth 16:0/18:1 biomarker \> 20 ng/ml (indicates at least 2 heavy drinking episodes in past two weeks); 2. have a dsm-5 diagnosis of a current aud as assessed by the structured clinical interview for dsm-5; 3. 18+ (individuals over 65 will be assessed for cognitive impairments) 4. are not receiving treatment for aud 5. are able to complete virtual study visits via zoom exclusion criteria: 1. have a current diagnosis of severe substance use disorder (other than aud, tobacco, and cannabis); 2. peth biomarker ≤ 20 ng/ml (indicates no heavy drinking in past month) 3. inability to provide informed consent based on the ubacc or maccat-cr; 4. alcohol withdrawal-related seizure or hospitalization in prior 12 months; 5. psychiatrically or medically unsafe to participate, as assessed by the pi; and/or 6. currently enrolled in alcohol treatment or another alcohol treatment study.

Keywords: contingency management alcohol abstinence adult biological markers blood clinical effectiveness cognitive therapy blood collection ethyl glucuronide health care costs heavy drinking addictions neuroclinical assessment cognition incentives phosphatidylethanol incentive salience anhedonia longitudinal studies prediction of response to therapy randomized clinical trial telehealth virtual health video conference